# WIA-AUG-013: Augmentation Safety Specification v1.0

> **Standard ID:** WIA-AUG-013
> **Version:** 1.0.0
> **Published:** 2025-12-26
> **Status:** Active
> **Authors:** WIA Human Augmentation Safety Group

---

## Table of Contents

1. [Introduction](#1-introduction)
2. [Safety Classification Framework](#2-safety-classification-framework)
3. [Risk Assessment Methodology](#3-risk-assessment-methodology)
4. [Biocompatibility Requirements](#4-biocompatibility-requirements)
5. [Failure Mode Analysis](#5-failure-mode-analysis)
6. [Safety Testing Protocols](#6-safety-testing-protocols)
7. [Emergency Procedures](#7-emergency-procedures)
8. [Long-term Monitoring](#8-long-term-monitoring)
9. [Implementation Guidelines](#9-implementation-guidelines)
10. [References](#10-references)

---

## 1. Introduction

### 1.1 Purpose

This specification defines comprehensive safety standards for human augmentation technologies, including risk assessment frameworks, biocompatibility requirements, and emergency protocols to ensure the safe development and deployment of augmentation devices.

### 1.2 Scope

The standard covers:
- Safety classification of augmentation devices
- Risk assessment methodologies
- Biocompatibility testing requirements
- Failure mode and effects analysis
- Emergency response procedures
- Long-term safety monitoring

### 1.3 Philosophy

**弘益人間 (Benefit All Humanity)** - Human augmentation technologies should enhance human capabilities while maintaining the highest safety standards. This specification ensures that technological advancement does not compromise human health and well-being.

### 1.4 Terminology

- **Augmentation**: Any technology that enhances human physical or cognitive capabilities
- **Implant**: A device surgically placed inside the human body
- **Biocompatibility**: Ability of a material to perform without adverse response
- **FMEA**: Failure Mode and Effects Analysis
- **Risk Priority Number (RPN)**: Quantitative risk assessment metric

---

## 2. Safety Classification Framework

### 2.1 Classification Levels

Augmentation devices are classified into five safety levels based on invasiveness and risk:

| Level | Name | Invasiveness | Risk | Examples |
|-------|------|--------------|------|----------|
| 1 | Minimal | None | Very Low | Smart glasses, fitness trackers |
| 2 | Low | Non-invasive contact | Low | Hearing aids, exoskeletons |
| 3 | Moderate | Minimally invasive | Moderate | Subcutaneous implants, pacemakers |
| 4 | High | Invasive | High | Neural interfaces, cochlear implants |
| 5 | Critical | Deeply invasive | Very High | Cognitive implants, brain chips |

### 2.2 Classification Criteria

```
Classification Score = Σ(Ci × Wi)
```

Where:
- `Ci` = Criterion score (1-10)
- `Wi` = Weight factor

Criteria:
1. Invasiveness depth (W=0.25)
2. Proximity to vital organs (W=0.20)
3. Reversibility potential (W=0.15)
4. Failure consequence severity (W=0.20)
5. Long-term biological interaction (W=0.20)

### 2.3 Classification Boundaries

```
Level 1: Score 1-15
Level 2: Score 16-30
Level 3: Score 31-50
Level 4: Score 51-75
Level 5: Score 76-100
```

### 2.4 Classification Algorithm

```typescript
interface ClassificationInput {
  invasiveness: number;         // 1-10
  vitalProximity: number;       // 1-10
  reversibility: number;        // 1-10 (10 = irreversible)
  failureConsequence: number;   // 1-10
  biologicalInteraction: number; // 1-10
}

function classifyDevice(input: ClassificationInput): SafetyLevel {
  const score =
    input.invasiveness * 0.25 +
    input.vitalProximity * 0.20 +
    input.reversibility * 0.15 +
    input.failureConsequence * 0.20 +
    input.biologicalInteraction * 0.20;

  if (score <= 1.5) return 'Level1';
  if (score <= 3.0) return 'Level2';
  if (score <= 5.0) return 'Level3';
  if (score <= 7.5) return 'Level4';
  return 'Level5';
}
```

---

## 3. Risk Assessment Methodology

### 3.1 Risk Priority Number (RPN)

The Risk Priority Number quantifies overall risk:

```
RPN = Severity × Occurrence × Detection
```

Where:
- `Severity` = Impact of failure (1-10)
- `Occurrence` = Probability of occurrence (1-10)
- `Detection` = Difficulty of detection (1-10)

### 3.2 Severity Scale

| Score | Level | Description |
|-------|-------|-------------|
| 1 | Negligible | No noticeable effect |
| 2-3 | Minor | Slight inconvenience, no injury |
| 4-5 | Moderate | Temporary discomfort, minor injury |
| 6-7 | Serious | Significant injury, medical attention required |
| 8-9 | Critical | Severe injury, hospitalization required |
| 10 | Catastrophic | Life-threatening or fatal |

### 3.3 Occurrence Scale

| Score | Level | Probability |
|-------|-------|-------------|
| 1 | Remote | < 0.001% |
| 2-3 | Low | 0.001% - 0.1% |
| 4-6 | Moderate | 0.1% - 1% |
| 7-8 | High | 1% - 5% |
| 9-10 | Very High | > 5% |

### 3.4 Detection Scale

| Score | Level | Description |
|-------|-------|-------------|
| 1 | Certain | Always detected before harm |
| 2-3 | High | High probability of detection |
| 4-5 | Moderate | May be detected |
| 6-7 | Low | Unlikely to be detected |
| 8-10 | Very Low | Cannot be detected |

### 3.5 RPN Thresholds

| RPN Range | Risk Level | Action Required |
|-----------|------------|-----------------|
| 1-50 | Low | Standard monitoring |
| 51-100 | Moderate | Enhanced monitoring |
| 101-200 | High | Risk mitigation required |
| 201-500 | Critical | Major redesign required |
| 501-1000 | Unacceptable | Do not proceed |

### 3.6 Risk Assessment Process

```
1. Identify all potential failure modes
2. For each failure mode:
   a. Assign Severity score
   b. Assign Occurrence score
   c. Assign Detection score
   d. Calculate RPN
3. Prioritize by RPN
4. Develop mitigation strategies
5. Recalculate RPN after mitigation
6. Document all assessments
```

---

## 4. Biocompatibility Requirements

### 4.1 Material Testing Requirements

All augmentation materials must pass ISO 10993 biocompatibility testing:

| Test Category | ISO Standard | Required For |
|---------------|--------------|--------------|
| Cytotoxicity | ISO 10993-5 | All levels |
| Sensitization | ISO 10993-10 | Level 2+ |
| Irritation | ISO 10993-10 | Level 2+ |
| Systemic Toxicity | ISO 10993-11 | Level 3+ |
| Genotoxicity | ISO 10993-3 | Level 3+ |
| Implantation | ISO 10993-6 | Level 3+ |
| Carcinogenicity | ISO 10993-3 | Level 4+ |
| Reproductive Toxicity | ISO 10993-3 | Level 5 |

### 4.2 Material Classification

```typescript
interface MaterialClassification {
  category: 'Inert' | 'Bioactive' | 'Biodegradable';
  contactDuration: 'Limited' | 'Prolonged' | 'Permanent';
  contactType: 'Surface' | 'External' | 'Implant';
  tissueContact: 'Skin' | 'Mucosal' | 'Bone' | 'Blood' | 'Neural';
}
```

### 4.3 Approved Materials

| Material | Classification | Approved Uses |
|----------|---------------|---------------|
| Titanium (Ti6Al4V) | Inert | Bone implants, housings |
| Medical-grade Silicone | Bioactive | Flexible components |
| PEEK | Inert | Structural components |
| Platinum-Iridium | Inert | Neural electrodes |
| Parylene C | Inert | Coatings, insulation |

### 4.4 Coating Requirements

For neural interfaces and blood-contacting devices:

```
Coating Thickness: 1-10 μm
Porosity: < 0.1%
Adhesion Strength: > 5 MPa
Biofilm Resistance: Required
Ionic Conductivity: Application-specific
```

---

## 5. Failure Mode Analysis

### 5.1 FMEA Requirements

All Level 3+ devices must complete a comprehensive FMEA:

```typescript
interface FailureMode {
  id: string;
  component: string;
  failureType: string;
  cause: string;
  effect: string;
  severity: number;
  occurrence: number;
  detection: number;
  rpn: number;
  mitigation: string;
  owner: string;
  deadline: Date;
}
```

### 5.2 Common Failure Categories

#### 5.2.1 Mechanical Failures
- Structural fracture
- Connector failure
- Seal degradation
- Wear and fatigue

#### 5.2.2 Electrical Failures
- Short circuit
- Open circuit
- Power failure
- Signal interference

#### 5.2.3 Biological Failures
- Immune rejection
- Infection
- Tissue necrosis
- Encapsulation

#### 5.2.4 Software Failures
- Algorithm errors
- Communication loss
- Calibration drift
- Security breach

### 5.3 Mitigation Strategies

| Failure Type | Primary Mitigation | Secondary Mitigation |
|--------------|-------------------|---------------------|
| Mechanical | Redundant design | Material upgrade |
| Electrical | Isolation/shielding | Backup systems |
| Biological | Biocoatings | Anti-inflammatory |
| Software | Failsafe modes | Remote update |

---

## 6. Safety Testing Protocols

### 6.1 Pre-Clinical Testing

Required for all Level 2+ devices:

```
1. Bench Testing
   - Mechanical stress testing (10⁶ cycles)
   - Electrical safety testing
   - Environmental testing (-40°C to +60°C)
   - Sterilization validation

2. In-Vitro Testing
   - Cell culture compatibility
   - Corrosion testing
   - Leaching analysis

3. In-Vivo Testing (Animal)
   - Acute implantation (30 days)
   - Chronic implantation (6-12 months)
   - Histopathology
```

### 6.2 Clinical Testing Requirements

| Level | Phase I | Phase II | Phase III | Post-Market |
|-------|---------|----------|-----------|-------------|
| 3 | 10 subjects | 50 subjects | 200 subjects | 2 years |
| 4 | 20 subjects | 100 subjects | 500 subjects | 5 years |
| 5 | 30 subjects | 200 subjects | 1000 subjects | 10 years |

### 6.3 Testing Data Requirements

```json
{
  "deviceId": "AUG-2025-001",
  "testPhase": "Phase II",
  "subjects": 100,
  "duration": "12 months",
  "endpoints": {
    "primary": ["safety", "functionality"],
    "secondary": ["quality of life", "user satisfaction"]
  },
  "adverseEvents": {
    "serious": 0,
    "moderate": 3,
    "minor": 12
  },
  "successRate": 0.97,
  "confidence": 0.95
}
```

---

## 7. Emergency Procedures

### 7.1 Emergency Categories

```
Category A: Life-threatening - Immediate response
Category B: Serious - Response within 1 hour
Category C: Moderate - Response within 24 hours
Category D: Minor - Scheduled response
```

### 7.2 Emergency Response Protocol

```
1. Detection (Automatic or Manual)
   ↓
2. Classification (A/B/C/D)
   ↓
3. Notification (User, Medical team, Manufacturer)
   ↓
4. Safe Mode Activation
   ↓
5. Medical Response
   ↓
6. Device Assessment
   ↓
7. Resolution or Removal
   ↓
8. Documentation and Reporting
```

### 7.3 Safe Mode Requirements

All Level 3+ devices must implement safe modes:

```typescript
interface SafeMode {
  trigger: 'manual' | 'automatic' | 'remote';
  actions: string[];
  powerState: 'off' | 'minimal' | 'backup';
  communication: 'active' | 'beacon' | 'silent';
  reversible: boolean;
  timeout: number; // seconds
}

const defaultSafeMode: SafeMode = {
  trigger: 'automatic',
  actions: ['cease_active_functions', 'maintain_vital_support'],
  powerState: 'minimal',
  communication: 'beacon',
  reversible: true,
  timeout: 3600
};
```

### 7.4 Device Removal Protocol

For emergencies requiring device removal:

```
1. Stabilize patient
2. Assess device status
3. Plan removal strategy
4. Surgical removal
5. Post-operative care
6. Device analysis
7. Root cause investigation
8. Regulatory reporting
```

---

## 8. Long-term Monitoring

### 8.1 Monitoring Requirements

| Level | Frequency | Duration | Data Points |
|-------|-----------|----------|-------------|
| 1 | Annual | 2 years | Basic metrics |
| 2 | Quarterly | 5 years | Standard metrics |
| 3 | Monthly | 10 years | Extended metrics |
| 4 | Weekly | Lifetime | Comprehensive |
| 5 | Continuous | Lifetime | Full telemetry |

### 8.2 Monitoring Data Schema

```typescript
interface MonitoringData {
  deviceId: string;
  timestamp: Date;
  metrics: {
    powerLevel: number;           // 0-100%
    signalQuality: number;        // 0-100%
    operatingTemperature: number; // Celsius
    impedance: number[];          // Ohms per channel
    functionality: number;        // 0-100%
    biomarkers: Biomarker[];
  };
  alerts: Alert[];
  userFeedback: UserFeedback;
}

interface Biomarker {
  name: string;
  value: number;
  unit: string;
  normal: { min: number; max: number };
  status: 'normal' | 'warning' | 'critical';
}
```

### 8.3 Alert Thresholds

```
Power Level:
  - Warning: < 20%
  - Critical: < 5%

Signal Quality:
  - Warning: < 70%
  - Critical: < 50%

Temperature:
  - Warning: > 38°C or < 35°C
  - Critical: > 40°C or < 33°C

Impedance (Neural):
  - Warning: > 1 MΩ or < 100 Ω
  - Critical: > 5 MΩ or < 10 Ω
```

### 8.4 Reporting Requirements

```
Adverse Event Reporting:
- Serious: Within 24 hours
- Moderate: Within 7 days
- Minor: Monthly summary

Periodic Reports:
- Safety Summary: Quarterly
- Efficacy Report: Semi-annually
- Comprehensive Review: Annually
```

---

## 9. Implementation Guidelines

### 9.1 Certification Requirements

To achieve WIA-AUG-013 certification:

```
1. Safety Classification (Section 2)
   - Complete classification assessment
   - Submit documentation

2. Risk Assessment (Section 3)
   - Complete FMEA
   - RPN below threshold

3. Biocompatibility (Section 4)
   - Pass all required ISO 10993 tests
   - Material traceability

4. Pre-Clinical Testing (Section 6)
   - Complete bench testing
   - Animal studies (if required)

5. Clinical Testing (Section 6)
   - Phase I/II/III trials
   - Statistical significance

6. Safety Systems (Section 7)
   - Safe mode implementation
   - Emergency protocols

7. Monitoring System (Section 8)
   - Real-time monitoring capability
   - Reporting infrastructure
```

### 9.2 Documentation Requirements

```
Required Documents:
□ Device Master File
□ Risk Assessment Report
□ Biocompatibility Test Reports
□ Clinical Trial Data
□ Manufacturing Process Validation
□ Sterilization Validation
□ Software Validation (if applicable)
□ Labeling and Instructions for Use
□ Training Materials
□ Post-Market Surveillance Plan
```

### 9.3 API Interface

```typescript
interface SafetyAssessment {
  deviceId: string;
  classification: SafetyLevel;
  rpn: number;
  biocompatibility: BiocompatibilityResult;
  testResults: TestResult[];
  certificationStatus: 'pending' | 'approved' | 'rejected';
  validUntil: Date;
}

interface AssessmentRequest {
  device: DeviceInfo;
  manufacturer: ManufacturerInfo;
  testData: TestData[];
  documentation: Document[];
}

function assessSafety(request: AssessmentRequest): SafetyAssessment;
function validateCompliance(deviceId: string): ComplianceResult;
function generateReport(deviceId: string, format: 'pdf' | 'json'): Report;
```

---

## 10. References

### 10.1 International Standards

1. ISO 10993 - Biological evaluation of medical devices
2. ISO 14971 - Medical devices — Application of risk management
3. IEC 60601-1 - Medical electrical equipment — General requirements
4. IEC 62304 - Medical device software — Software life cycle processes
5. ISO 13485 - Medical devices — Quality management systems

### 10.2 Regulatory Guidelines

- FDA Guidance for Industry: Cybersecurity in Medical Devices
- EU MDR 2017/745 - Medical Device Regulation
- IMDRF Guidelines for Software as a Medical Device

### 10.3 WIA Standards

- WIA-AUG-001: Human Augmentation General
- WIA-AUG-014: Human-Machine Interface
- WIA-BCI: Brain-Computer Interface
- WIA-SEC: Security Standards
- WIA-MED: Medical Device Standards

---

## Appendix A: Risk Assessment Worksheet

```
Device: _______________
Date: _______________
Assessor: _______________

| ID | Component | Failure Mode | Cause | Effect | S | O | D | RPN | Mitigation |
|----|-----------|--------------|-------|--------|---|---|---|-----|------------|
| 1  |           |              |       |        |   |   |   |     |            |
| 2  |           |              |       |        |   |   |   |     |            |
...

Total RPN: ___
Maximum Single RPN: ___
Assessment Result: □ Pass □ Fail □ Conditional
```

## Appendix B: Biocompatibility Test Checklist

```
Device Classification: Level ___
Contact Duration: ___

Required Tests:
□ Cytotoxicity (ISO 10993-5)
□ Sensitization (ISO 10993-10)
□ Irritation (ISO 10993-10)
□ Systemic Toxicity (ISO 10993-11)
□ Genotoxicity (ISO 10993-3)
□ Implantation (ISO 10993-6)
□ Carcinogenicity (ISO 10993-3)
□ Reproductive Toxicity (ISO 10993-3)

Results Summary:
Test                  | Result    | Date       | Lab
---------------------|-----------|------------|-----
                     |           |            |
```

---

**弘益人間 (홍익인간) · Benefit All Humanity**

*WIA-AUG-013 Specification v1.0*
*© 2025 SmileStory Inc. / WIA*
*MIT License*
